CTNM

Contineum Therapeutics Inc

9.39

Oct 30 • 3:59 PM ET +0.06 (0.64%)

9.58

Aftermarket • 5:00 PM ET +0.19 (2.02%)

Healthcare Biotechnology USA Small NASD

Peers: PLRX AVLN IMUX VCRE PRTA ALEC DNLI ABOS LTGO SPTX

| Held by: VTI IWM VXF IWN VTWO IBB XPH SCHA DFAS IWC

Scroll to Statements

Index	RUT
Market Cap	353.26M
Enterprise Value	123.28M
Income	-57.56M
Sales	0.00M
Book/sh	6.37
Cash/sh	6.29
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	51
IPO	Apr 05, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.47
P/C	1.49
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	37.17
Current Ratio	37.17
Debt/Eq	0.03
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-1.74
EPS next Y	-2.00
EPS next Q	-0.45
EPS this Y	21.31%
EPS next Y	-16.84%
EPS next 5Y	2.63%
EPS past 3/5Y	-30.91% -
Sales past 3/5Y	- -
EPS Y/Y TTM	21.01%
Sales Y/Y TTM	-
EPS Q/Q	34.71%
Sales Q/Q	-
Earnings	Jul 30 AMC
EPS/Sales Surpr.	10.87% -

Insider Own	21.27%
Insider Trans	-0.93%
Inst Own	81.24%
Inst Trans	0.22%
ROA	-26.57%
ROE	-28.01%
ROIC	-23.60%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-1.53%
SMA50	-26.08%
SMA200	-30.72%
Trades

Shs Outstand	32.95M
Shs Float	29.62M
Short Float	12.34%
Short Ratio	4.42
Short Interest	3.66M
52W High	17.78 -47.20%
52W Low	6.72 39.63%
Volatility	8.98% 10.40%
ATR (14)	0.97
RSI (14)	43.03
Beta	0.91
Rel Volume	0.55
Avg Volume	826.62K
Volume	458,631

Perf Week	13.00%
Perf Month	-27.71%
Perf Quarter	-41.05%
Perf Half Y	-28.86%
Perf YTD	-17.85%
Perf Year	-10.91%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.50
Target Price	22.14
Prev Close	9.33
Price	9.39
Change %	0.64%

Consensus

Buy

Avg. Price Target

$22.14

Implied Upside

+135.8%

Analysts6incl. previous ratings

Rating Distribution4 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 13, 2026	Downgrade	RRobert W. Baird	Outperform → Neutral	$14	+49.1%
Jan 08, 2026	Downgrade	MMorgan Stanley	Overweight → Equal-Weight	$14	+49.1%
Nov 13, 2025	Initiated	LLeerink Partners	Outperform	$22	+134.3%
Sep 25, 2025	Initiated	LLeerink Partners	Outperform	$20	+113.0%
Jun 20, 2025	Initiated	WWilliam Blair	Outperform
Oct 22, 2024	Initiated	RRobert W. Baird	Outperform	$32	+240.8%
Apr 30, 2024	Initiated	SStifel	Buy	$29	+208.8%
Apr 30, 2024	Initiated	RRBC Capital Mkts	Outperform	$30	+219.5%
Apr 30, 2024	Initiated	MMorgan Stanley	Overweight	$25	+166.2%

Oct-29-26 04:05PM	Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference (Business Wire)
Oct-12-26 08:42AM	Contineum Therapeutics Shares Surge 27% After Bristol Myers Squibb Reports Positive Phase 3 Trial Results (InvestorsHub) -35.99%
07:55AM	Contineum drops 25% on mixed Bristol Myers IPF data; Stifel keeps Buy rating (Investing.com)
Sep-30-26 12:22PM	Bristol Myers trial revisions shake confidence in new class of fibrosis drugs (BioPharma Dive) +16.70%
Sep-15-26 01:13PM	FDA clears first generic radioligand drug; Sionna turns to layoffs (BioPharma Dive) -6.75%
05:32PM	Loading…
Sep-14-26 05:32PM	CTNM Stock Slumps 10% After-Hours Whats The JNJ Connection? (Stocktwits)
04:05PM	Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder (Business Wire)
Aug-25-26 04:05PM	Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference (Business Wire)
Jul-30-26 04:05PM	Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones (Business Wire) +9.53%
Jun-30-26 04:05PM	Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry (Business Wire) +9.27% -7.02%
Jun-01-26 04:05PM	Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference (Business Wire) -5.42%
May-15-26 04:05PM	Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.27%
May-12-26 04:05PM	Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference (Business Wire)
May-11-26 04:05PM	Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference (Business Wire) -6.06%
May-05-26 04:05PM	Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones (Business Wire)
04:05PM	Loading…
May-01-26 04:05PM	Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.20%
Apr-30-26 04:05PM	Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain (Business Wire) +6.48%
Mar-13-26 04:05PM	Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.20%
Mar-05-26 04:05PM	Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones (Business Wire) -7.07%
Mar-03-26 04:05PM	Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference (Business Wire) -8.08% +5.39%
Mar-02-26 08:25AM	Beat the Market the Zacks Way: Contineum Therapeutics, Suzano, PepsiCo in Focus (Zacks)
Feb-18-26 04:05PM	Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.12%
Feb-04-26 09:40AM	Is Contineum Therapeutics, Inc. (CTNM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jan-28-26 04:05PM	Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-31-25 12:00PM	Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	Wall Street Analysts See a 91.49% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High? (Zacks)
Dec-11-25 10:24PM	Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering (Business Wire) -11.02%
04:05PM	Contineum Therapeutics Announces Proposed $75.0 Million Public Offering (Business Wire)
Nov-24-25 04:05PM	Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference (Business Wire) -5.34%
Nov-21-25 01:44AM	A brain biotechs top drug fails against MS (BioPharma Dive) -10.43%
04:05PM	Loading…
Nov-20-25 04:05PM	Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) (Business Wire)
Oct-30-25 04:05PM	Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones (Business Wire)
Sep-18-25 08:05AM	Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 (Business Wire)
Aug-28-25 04:05PM	Contineum Therapeutics to Present at September Investor Conferences (Business Wire)
Aug-08-25 09:55AM	Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 235.81%: Read This Before Placing a Bet (Zacks)
Aug-05-25 04:05PM	Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones (Business Wire) +5.50%
Jun-25-25 08:15AM	Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 (Business Wire)
May-15-25 04:05PM	Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference (Business Wire) -10.91%
May-14-25 04:05PM	Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones (Business Wire)
Apr-28-25 04:05PM	Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development (Business Wire)
Mar-17-25 04:05PM	Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors (Business Wire) +5.85% +6.09%
Mar-12-25 04:05PM	Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum (Business Wire) -5.56%
Mar-06-25 04:05PM	Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones (Business Wire) +5.57% +5.12%
Mar-04-25 04:05PM	Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791 (Business Wire) -5.16%
Mar-03-25 04:05PM	Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference (Business Wire) -6.39%
Jan-08-25 04:05PM	Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) (Business Wire)
Jan-06-25 08:00AM	RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors (GlobeNewswire)
Dec-16-24 04:05PM	Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 (Business Wire)
Nov-25-24 08:05AM	Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference (Business Wire) +9.01%
Nov-18-24 08:05AM	Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain (Business Wire) -8.02%
Nov-13-24 04:05PM	Contineum Therapeutics to Attend Upcoming Investor Conferences (Business Wire)
Nov-06-24 04:05PM	Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (Business Wire) +7.60%
Aug-28-24 04:05PM	Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences (Business Wire) -7.00%
Aug-13-24 04:05PM	Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (Business Wire) -6.06% +6.21%
Jul-31-24 04:05PM	Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis (Business Wire) -5.33%
Jun-24-24 04:05PM	Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors (Business Wire)
Jun-04-24 04:05PM	Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference (Business Wire)
Jun-03-24 04:05PM	Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary (Business Wire)
May-20-24 04:05PM	Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors (Business Wire)
May-16-24 04:05PM	Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
Apr-04-24 09:02PM	Contineum Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Daniel Lorrain	Officer	Oct 01 '26	Proposed Sale	13.42	4,170	55,961		Oct 01 04:21 PM
Stengone Carmine N.	CEO and President	Sep 08 '26	Option Exercise	1.01	2,500	2,525	19,717	Sep 08 06:08 PM
Stengone Carmine N.	CEO and President	Sep 08 '26	Sale	16.46	2,500	41,142	17,217	Sep 08 06:08 PM
CARMINE STENGONE	Director	Sep 08 '26	Proposed Sale	16.70	2,500	41,750		Sep 08 04:28 PM
Daniel Lorrain	Officer	Sep 01 '26	Proposed Sale	16.24	9,520	154,605		Sep 01 04:35 PM
Stengone Carmine N.	CEO and President	Aug 03 '26	Option Exercise	1.01	2,500	2,525	19,717	Aug 03 06:14 PM
Stengone Carmine N.	CEO and President	Aug 03 '26	Sale	16.01	2,500	40,029	17,217	Aug 03 06:14 PM
CARMINE STENGONE	Director	Aug 03 '26	Proposed Sale	15.49	2,500	38,725		Aug 03 04:19 PM
Daniel Lorrain	Officer	Aug 03 '26	Proposed Sale	15.49	9,520	147,465		Aug 03 04:18 PM
Lorrain Daniel S.	Chief Scientific Officer	Jul 08 '26	Option Exercise	1.01	1,015	1,025	136,217	Jul 10 05:20 PM
Lorrain Daniel S.	Chief Scientific Officer	Jul 09 '26	Option Exercise	1.01	25	25	135,227	Jul 10 05:20 PM
Lorrain Daniel S.	Chief Scientific Officer	Jul 08 '26	Sale	16.00	1,015	16,240	135,202	Jul 10 05:20 PM
Lorrain Daniel S.	Chief Scientific Officer	Jul 09 '26	Sale	16.00	25	400	135,202	Jul 10 05:20 PM
Stengone Carmine N.	CEO and President	Jul 08 '26	Option Exercise	1.01	2,500	2,525	19,717	Jul 08 06:49 PM
Stengone Carmine N.	CEO and President	Jul 08 '26	Sale	16.00	2,500	40,000	17,217	Jul 08 06:49 PM
CARMINE STENGONE	Director	Jul 08 '26	Proposed Sale	14.56	2,500	36,400		Jul 08 04:39 PM
Lorrain Daniel S.	Chief Scientific Officer	Jun 30 '26	Option Exercise	1.01	28,826	29,114	168,198	Jul 02 05:47 PM
Lorrain Daniel S.	Chief Scientific Officer	Jul 01 '26	Option Exercise	1.01	4,183	4,225	143,555	Jul 02 05:47 PM
Lorrain Daniel S.	Chief Scientific Officer	Jun 30 '26	Sale	16.04	28,826	462,288	139,372	Jul 02 05:47 PM
Lorrain Daniel S.	Chief Scientific Officer	Jul 01 '26	Sale	15.84	8,353	132,290	135,202	Jul 02 05:47 PM
Watkins Tim	CMO & Head of Development	Jun 30 '26	Option Exercise	4.50	10,833	48,748	19,794	Jul 01 07:04 PM
Watkins Tim	CMO & Head of Development	Jun 30 '26	Sale	16.02	10,833	173,590	8,961	Jul 01 07:04 PM
Stengone Carmine N.	CEO and President	Jun 30 '26	Option Exercise	1.07	10,000	10,725	27,217	Jul 01 07:04 PM
Stengone Carmine N.	CEO and President	Jun 30 '26	Sale	16.01	10,000	160,080	17,217	Jul 01 07:04 PM
Daniel Lorrain	Officer	Jul 01 '26	Proposed Sale	16.39	9,520	156,033		Jul 01 04:34 PM
Daniel Lorrain	Officer	Jun 30 '26	Proposed Sale	15.00	28,826	432,390		Jun 30 04:38 PM
CARMINE STENGONE	Director	Jun 30 '26	Proposed Sale	15.00	10,000	150,000		Jun 30 04:38 PM
TIMOTHY WATKINS	Officer	Jun 30 '26	Proposed Sale	15.00	10,833	162,495		Jun 30 04:37 PM
Lorrain Daniel S.	Chief Scientific Officer	Jun 01 '26	Sale	13.16	4,170	54,862	139,372	Jun 01 06:08 PM
DANIEL LORRAIN	Officer	Jun 01 '26	Proposed Sale	13.49	4,170	56,253		Jun 01 04:19 PM
Lorrain Daniel S.	Chief Scientific Officer	May 01 '26	Sale	13.12	4,170	54,694	143,542	May 01 05:42 PM
DANIEL LORRAIN	Officer	May 01 '26	Proposed Sale	12.82	4,170	53,459		May 01 04:47 PM
Lorrain Daniel S.	Chief Scientific Officer	Apr 06 '26	Sale	13.43	4,170	56,014	147,712	Apr 06 05:43 PM
DANIEL LORRAIN	Officer	Apr 06 '26	Proposed Sale	13.44	914	12,284		Apr 06 04:33 PM
Lorrain Daniel S.	Chief Scientific Officer	Mar 02 '26	Sale	15.01	4,170	62,585	151,882	Mar 02 06:30 PM
Watkins Tim	CMO & Head of Development	Mar 02 '26	Option Exercise	4.50	3,611	16,250	3,611	Mar 02 06:28 PM
Watkins Tim	CMO & Head of Development	Mar 02 '26	Sale	15.02	3,611	54,220	0	Mar 02 06:28 PM
Stengone Carmine N.	CEO and President	Feb 24 '26	Option Exercise	1.26	4,400	5,544	19,354	Feb 26 04:40 PM
Stengone Carmine N.	CEO and President	Feb 25 '26	Option Exercise	1.26	2,700	3,402	17,654	Feb 26 04:40 PM
Stengone Carmine N.	CEO and President	Feb 24 '26	Sale	16.02	4,400	70,486	14,954	Feb 26 04:40 PM
Stengone Carmine N.	CEO and President	Feb 25 '26	Sale	16.02	2,700	43,242	14,954	Feb 26 04:40 PM
Lorrain Daniel S.	Chief Scientific Officer	Feb 24 '26	Option Exercise	1.01	4,300	4,343	160,352	Feb 26 04:39 PM
Lorrain Daniel S.	Chief Scientific Officer	Feb 25 '26	Option Exercise	1.01	3,824	3,862	159,876	Feb 26 04:39 PM
Lorrain Daniel S.	Chief Scientific Officer	Feb 24 '26	Sale	16.03	4,300	68,936	156,052	Feb 26 04:39 PM
Lorrain Daniel S.	Chief Scientific Officer	Feb 25 '26	Sale	16.01	3,824	61,228	156,052	Feb 26 04:39 PM
Lorrain Daniel S.	Chief Scientific Officer	Feb 19 '26	Option Exercise	1.01	100	101	156,152	Feb 20 04:05 PM
Lorrain Daniel S.	Chief Scientific Officer	Feb 19 '26	Sale	16.00	100	1,600	156,052	Feb 20 04:05 PM
Stengone Carmine N.	CEO and President	Feb 11 '26	Option Exercise	1.26	400	504	15,354	Feb 13 04:27 PM
Stengone Carmine N.	CEO and President	Feb 11 '26	Sale	16.00	400	6,400	14,954	Feb 13 04:27 PM
Lorrain Daniel S.	Chief Scientific Officer	Feb 11 '26	Option Exercise	1.01	400	404	156,452	Feb 13 04:26 PM
Lorrain Daniel S.	Chief Scientific Officer	Feb 11 '26	Sale	16.00	400	6,400	156,052	Feb 13 04:26 PM
DANIEL LORRAIN	Officer	Feb 11 '26	Proposed Sale	15.75	16,050	252,788		Feb 11 04:29 PM
CARMINE STENGONE	Director	Feb 11 '26	Proposed Sale	15.75	7,500	118,125		Feb 11 04:29 PM
Lorrain Daniel S.	Chief Scientific Officer	Feb 03 '26	Sale	14.94	4,170	62,305	156,052	Feb 05 04:24 PM
DANIEL LORRAIN	Officer	Feb 03 '26	Proposed Sale	14.38	4,170	59,965		Feb 03 04:32 PM
Watkins Tim	CMO & Head of Development	Jan 28 '26	Option Exercise	4.50	3,611	16,250	3,611	Jan 30 04:52 PM
Watkins Tim	CMO & Head of Development	Jan 28 '26	Sale	14.18	3,611	51,188	0	Jan 30 04:52 PM
Lorrain Daniel S.	Chief Scientific Officer	Jan 05 '26	Sale	10.44	4,170	43,543	160,222	Jan 06 04:16 PM
DANIEL LORRAIN	Officer	Jan 05 '26	Proposed Sale	11.39	4,170	47,496		Jan 05 04:42 PM
Watkins Tim	CMO & Head of Development	Dec 29 '25	Option Exercise	4.50	3,611	16,250	3,611	Dec 30 04:12 PM
Watkins Tim	CMO & Head of Development	Dec 29 '25	Sale	12.06	3,611	43,558	0	Dec 30 04:12 PM
Lorrain Daniel S.	Chief Scientific Officer	Dec 23 '25	Sale	12.23	4,170	51,009	164,392	Dec 30 04:10 PM
TIMOTHY WATKINS	Officer	Dec 29 '25	Proposed Sale	12.41	10,833	134,438		Dec 29 04:25 PM
DANIEL LORRAIN	Officer	Dec 23 '25	Proposed Sale	12.26	4,170	51,124		Dec 23 04:20 PM

Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.

MSMr. Carmine N. Stengone MBA

Chief Financial OfficerMr. Peter T. Slover CPA

M.Sc.Dr. Timothy R. Watkins M.D.

Senior Manager of AccountingMs. Morgan Paulsen

Chief Science OfficerDr. Daniel S. Lorrain Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTNM

Contineum Therapeutics Inc

Upgrade your Finviz experience